Despite regrowth off treatment , overall reductions were observed , with a median ( interquartile range ) TLV of 4047 mL ( 3107-7402 mL ) at baseline and 3477 ( 2653-7131 mL ) at study completion ( -13.2 % ; P < .001 ) and with improved health-related QoL .